Comparing the Lack of Accountability Involving Vaccine Injuries—Global Review
National Vaccine Injury Compensation Program Vaccine Makers Face Growing Pressure Over Injury Claims as New Development Continues Global pharmaceutical companies are encountering increased scrutiny over vaccine injury compensation even as they push forward with next-generation COVID-19 vaccine development. Recent data shows manufacturers have approved less than 1% of injury claims while reporting record profits from vaccine sales. In the United States, the federal Countermeasures Injury Compensation Program (CICP) has approved only 50 claims out of approximately 13,000 filed, according to government statistics released this month. Meanwhile, Pfizer reported over $81 billion in vaccine-related revenue for 2021 alone. "The current system fails to balance corporate protections with individual rights," says Mae C. Quinn, Professor of Law at Penn State University. Quinn's recent analysis of global vaccine injury programs found that most countries' compensation systems rema...